A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease

Overall, our findings underscore CSF YWHAG:NPTX2 and the corresponding plasma signature as robust prognostic biomarkers for AD onset and progression beyond gold-standard biomarkers of Aβ, tau, and neurodegeneration and implicate synapse dysfunction as a core driver of AD dementia.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70856_102349
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease

Yann Le Guen, Amelia Farinas, Beth A. Stevens, Anthony D. Wagner et al.
Alzheimer s & Dementia
Alzheimer's disease research and treatments
article

A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease

Yann Le Guen, Amelia Farinas, Beth A. Stevens, Anthony D. Wagner, Daniel Western, Jingsha Chen, Chengran Yang, Tuomas Rauramaa, Ville Leinonen, Lena Karlsson, Hamilton Se‐Hwee Oh, Michael R. Duggan, Kathleen L. Poston, Ian H. Guldner, Divya Channappa, Nader Morshed, Sanna‐Kaisa Herukka, Deniz Yagmur Urey, Keenan A. Walker, Alexandra N. Trelle, Elizabeth C. Mormino, Nicolai Franzmeier, Alexander J. Ehrenberg, Oskar H. Hansson, Antti Johannes Luikku, Jigyasha Timsina, Zeyu Zhu, Ted N. Wilson, Anssi Lipponen, Tony Wyss‐Coray, Muhammad Ali, Mikko Hiltunen, Carlos Cruchaga, Yuanyuan Shen, Rebecca F. Gottesman, Henrik Zetterberg, David A. A. Bennett, Josef Coresh
article en

Abstract

Overall, our findings underscore CSF YWHAG:NPTX2 and the corresponding plasma signature as robust prognostic biomarkers for AD onset and progression beyond gold-standard biomarkers of Aβ, tau, and neurodegeneration and implicate synapse dysfunction as a core driver of AD dementia.

Alzheimer s & DementiaVol. 21(S2)
Broad Institute (US), Boston Children's Hospital (US), Johns Hopkins University (US), University of Eastern Finland (FI), University of California, San Francisco (US), Neurosciences Institute (US), Lund University (SE), Washington University in St. Louis (US), Hong Kong Science and Technology Parks Corporation (HK), LMU Klinikum (DE), Kuopio University Hospital (FI), Innovative Genomics Institute (US), National Institute of Neurological Disorders and Stroke (US), Munich Cluster for Systems Neurology (DE), UK Dementia Research Institute (GB), National Institute on Aging (US), Skåne University Hospital (SE), The London College (GB), University College London (GB), Rush University (US), New York University (US), Ludwig-Maximilians-Universität München (DE), University of Gothenburg (SE), University of California, Berkeley (US), Stanford University (US), Icahn School of Medicine at Mount Sinai (US)
Openalex Percentile: Top 33%
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.